Latest From MacroGenics Inc.
MacroGenics, Amgen, Celgene, Forty Seven and Iovance are all set to enjoy a good ASCO meeting with promising data for key products revealed in the abstract drop.
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- MacroGenics Inc.
- Senior Management
Scott Koenig, MD, PhD, Pres. & CEO
James Karrels, SVP, CFO
Ezio Bonvini, MD, SVP, Research & CSO
Eric Risser, VP, Bus. Dev. & Portfolio Mgmt. & CBO
Jon Wigginton, MD, SVP, Clin. Dev. & CMO
- Contact Info
Phone: (301) 251-5172
9704 Medical Center Dr.
Rockville, MD 20850
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.